On air · 2 of 3 networks
Eisai U.S. Neurology
- eisaineuro.com
- Healthcare & Life Sciences
- US
- 98 employees
Eisai U.S. Neurology’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 22. Watch Eisai U.S. Neurology with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 22 | Checked 28 Oct 2026 | See all 22 ads → | ||
| Meta | Running | 1 | Active ads on the Meta Ad Library, all countries | Checked 28 Oct 2026 | Collect them with the API → |
| None recorded | 0 | No ads found on the Google Ads Transparency Center | Checked 28 Oct 2026 | Collect them with the API → |
Eisai U.S. Neurology has 22 live LinkedIn ads. Its Facebook page had 1 active ad on 28 Oct 2026, and we recorded no Google ads on 28 Oct 2026.
Latest ads
- LINKEDIN · IMAGERecorded 17 Sept 2026
ICYMI: Our team spent a productive and inspiring four days at the CTAD Clinical Trials on Alzheimer's Disease conference, where we shared new research and had the pleasure of meeting several of our fellow attendees. Review the data we presented: https://ow.ly/osw250XG0xt #AlzheimersDisease #CTAD25
- LINKEDIN · IMAGERecorded 17 Sept 2026
New data release! We’re pleased to share our latest clinical research on an anti-amyloid beta-directed antibody, specifically the potential benefits of subcutaneous initiation dosing, continued treatment, real-world experience, and more at the Clinical Trials on Alzheimer’s Disease (CTAD) conference (CTAD Clinical Trials on Alzheimer's Disease) in San Diego. We appreciate and thank the study participants, investigators, and support staff for their hard work. Review our findings: https://bit.ly/4iAMLCX
- LINKEDIN · VIDEORecorded 17 Sept 2026
People living with #AlzheimersDisease (AD) may follow a progressive disease continuum that begins with an asymptomatic phase, continues to minor cognitive impairment, and ultimately results in dementia. An early AD diagnosis can enable patients to seek treatment and lifestyle changes that may help reduce cognitive and functional decline. Learn more about the AD continuum: https://ow.ly/yvm350X9KIp #neurology #EndAlz
- LINKEDIN · VIDEORecorded 17 Sept 2026
People living with Alzheimer’s disease (AD) may encounter a variety of struggles, including effects on their mental well-being. We understand the challenges these individuals may face and are committed to providing support. Learn more: https://ow.ly/CLAF50X9KFa #AlzheimersDisease #neurology #EndAlz
- LINKEDIN · VIDEORecorded 17 Sept 2026
Darren Gitelman, MD rounds out our Unlocking Alzheimer’s Disease series by discussing what clinicians and care partners can do to help address the needs of patients diagnosed with early #AlzheimersDisease. Learn more by watching the video on our YouTube channel: https://ow.ly/hcH750WPMTo #EndAlz
- LINKEDIN · VIDEORecorded 17 Sept 2026
In the latest episode of our Unlocking Alzheimer’s Disease series, Darren Gitelman, MD discusses challenges clinicians may face when implementing treatment protocols, as well as how the lack of diverse populations in clinical trials may impact treatment efficacy and safety. Learn more by watching the video on our YouTube channel: https://ow.ly/6z4p50WPMQS #AlzheimersDisease #EndAlz
6 of 22 adsSign up to see every Eisai U.S. Neurology ad, filter by format and date, and get alerts on new ones.
See all 22 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.